Clinical Trial Detail

NCT ID NCT04039230
Title Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Therapies

Sacituzumab govitecan-hziy + Talazoparib

Age Groups: adult senior

No variant requirements are available.